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ABSTRACT
We have previously shown that LHRH agonists exert a direct and
specific inhibitory action on the proliferation of the androgen-inde-
pendent DU 145 prostate cancer cell line; however, the cellular mech-
anisms mediating this antiproliferative action are not well defined. It
is well known that the insulin-like growth factor (IGF) system plays
a crucial role in the local regulation of the growth of androgen-inde-
pendent prostate cancer. The present experiments were performed to
evaluate whether LHRH agonists might exert their antimitogenic
effect by interfering with the activity of the locally expressed IGF
system. To this purpose, the effects of the LHRH agonist Zoladex
(LHRH-A) on 1) the mitogenic action of IGF-I, 2) the tyrosine phos-
phorylation of type 1 IGF-I receptor (IGF-IR), 3) the concentration of
IGF-IR, and 4) the secretion of IGF-binding protein-3 were studied.
The results obtained show that in DU 145 cells, LHRH-A 1) coun-
teracts the mitogenic action of IGF-I in a dose-dependent manner, 2)
prevents the IGF-I-induced tyrosine phosphorylation of the IGF-IR,
3) reduces the concentration of IGF-IR without affecting its Kd value,
and 4) does not affect the secretion of IGF-binding protein-3 in the
conditioned medium from these cells.
These data suggest that LHRH agonists may inhibit the prolifer-
ation of human androgen-independent prostate tumor cells by inter-
fering with some of the cellular mechanisms mediating the stimula-
tory action of the IGF system. (Endocrinology 140: 329–334, 1999)
PROSTATE adenocarcinoma has become the second lead-ing cause of death from malignancies in men (1). In its
initial stages, the development and the progression of pros-
tate cancer are mainly regulated by androgens (2, 3); how-
ever, this pathology may eventually progress to a condition
in which hormone dependence is lost. Growth factors, either
exogenous or locally produced, have been shown to be in-
volved in the regulation of growth of prostate carcinoma (1).
In particular, the insulin-like growth factor (IGF) system has
been reported to exert a strong mitogenic action on prostate
cancer (4); moreover, serum IGF-I levels have recently been
correlated with prostate cancer risk (5). Androgen-indepen-
dent prostate cancer cells produce IGFs peptides (6–9), ex-
press type 1 IGF receptors (IGF-IR) (8–13), which are known
to mediate the biological activities of IGFs (14), and respond
to the mitogenic action of IGFs (7–11, 15, 16). IGF-binding
proteins (IGFBPs), which bind IGFs and modulate their ac-
tions, have also been shown to be produced by steroid-
unresponsive prostate cancer cells (9, 17–20).
The clinical utility of LHRH agonists for the treatment of
androgen-responsive prostate cancers is now well recog-
nized (2, 3). These compounds act mainly by suppressing the
activity of the pituitary-testicular axis (21); in addition, a
direct inhibitory action at the level of the tumor has been
found in our (22, 23) as well as other (24, 25) laboratories.
Recently, we demonstrated that LHRH agonists may also
exert a direct antiproliferative action on DU 145 cells, an
androgen-independent prostate cancer cell line, either in cul-
ture (26) or when inoculated into nude mice (27).
The present study was performed to investigate whether
LHRH agonists might exert their antiproliferative action on
DU 145 cells by interfering with the activity of the IGF sys-
tem. To this purpose, the effects of the LHRH agonist Zoladex
(LHRH-A) on 1) the proliferative action of IGF-I, 2) the ty-
rosine phosphorylation of IGF-IR, 3) the concentration of




The LHRH agonist Zoladex [d-Ser(tBu)6Aza-Gly-LHRH; LHRH-A]
was donated by Zeneca (Milan, Italy). Human recombinant IGF-I and
[125I]IGF-I (250 mCi/mg) were purchased from Amersham (Milan, It-
aly). IGF-IRa, a mouse monoclonal antibody to IGF-IR, was purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antiphospho-
tyrosine mouse monoclonal antibody (IgG2bk) and IGFBP-3 rabbit poly-
clonal antiserum were obtained from Upstate Biotechnology (Lake
Placid, NY). The enhanced chemiluminescence (ECL) Western blotting
kit (Amersham) was used for the detection of immunoprecipitated ty-
rosine-phosphorylated IGF receptor and IGFBP-3.
Cell culture
The cell line DU 145 was obtained from American Type Culture
Collection (Manassas, VA). These cells were derived from a brain me-
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tastasis of a human androgen-unresponsive prostate carcinoma; they
retain the androgen independence of the original tumor and do not
express the androgen receptor (28). DU 145 cells (passages 60–70) were
routinely grown in RPMI 1640 medium (Seromed Biochrom, Berlin,
Germany) supplemented with 5% FCS (Life Technologies, Paisley, Scot-
land, UK), glutamine (1 mmol/liter) and antibiotics (100 U/ml penicillin
G sodium and 100 mg/ml streptomycin sulfate) in a humidified atmo-
sphere of 5% CO2-95% air. Under these conditions, the doubling time
was 36 h.
Cell proliferation studies
Cell growth studies were performed on exponentially growing cells.
DU 145 cells were plated at a density of 2 3 104 cells in 60-mm dishes.
After 3 days, the seeding media were changed to RPMI 1640 supple-
mented with 2% FCS. Under these conditions, DU 145 cells have been
reported to positively respond to the mitogenic action of growth factors
(11). Cells were treated every day with IGF-I (10 ng/ml) in either the
absence or presence of different doses of LHRH-A (10210–1026 m). After
7 days of treatment, cells were harvested and counted, in a blind manner,
by hemocytometer. Previous studies from our laboratory have shown
that LHRH-A does not affect prostate cancer cell viability but, rather,
exerts an effect on cell proliferation (22).
Tyrosine phosphorylation of IGF-IR
Analysis of the tyrosine phosphorylation of IGF-IR has been per-
formed as previously described by Neuenschwander et al. (29), with
some modifications.
In preliminary experiments, cells were treated with IGF-I (75 ng/ml)
for different time periods (1–10 min) to evaluate the time course of the
stimulation of tyrosine kinase activity of IGF-IR. As the maximum level
of activity was found as early as 3 min in DU 145 cells (see Results), this
time period has been used for subsequent studies. For these preliminary
experiments, immunoprecipitation of IGF-IR and analysis of receptor
tyrosine phosphorylation were performed as follows.
To study the possible interaction of LHRH-A with the IGF-I-induced
tyrosine phosphorylation of IGF-IR, DU 145 cells were plated at a density
of 1 3 106 cells in 100-mm dishes in RPMI 1640 medium supplemented
with 5% FCS. After 2 days, cells were refed with 10 ml serum-free
medium for 24 h and then pretreated for 30 or 60 min with LHRH-A
(1026 m final concentration in the cells) before IGF-I stimulation (3 min).
At the end of the treatment, the experimental medium was removed, the
cell layer was rinsed with PBS, and cells were then harvested in 1 ml
RIPA buffer [0.05 M Tris-HCl (pH 7.7), 0.15 m NaCl, 0.8% Triton X-100,
0.8% sodium deoxycholate, 0.08% SDS, 10 mm EDTA, 100 mm Na3VO4,
50 mm NaF, 0.3 mm phenylmethylsulfonylfluoride, and 5 mm iodoacetic
acid] on ice for 10 min. Cell lysates were centrifuged at 15,000 3 g for
20 min; supernatants were immunoprecipitated with 2 mg/20 ml of the
monoclonal antibody IGF-IRa, raised against IGF-IR, for 15 min in the
presence of 10 ml rabbit antimouse IgG. Protein A-Sepharose (75 ml) was
added at room temperature for 30 min, and samples were then centri-
fuged at 4000 3 g for 5 min. Precipitated proteins were electrophoresed
by SDS-PAGE on a 7.5% polyacrylamide gel (30) and blotted onto a
nitrocellulose filter. Filters were incubated with antiphosphotyrosine
monoclonal antibody (1 mg/ml) for 1 h at room temperature and then
with an antimouse IgG at the final concentration of 1:5000. Antibody
bound to phosphotyrosine was detected with the ECL-Western blotting
detection system after a 5- to 10-min exposure to a Hyperfilm-ECL x-ray
film (Amersham, Milan, Italy) at room temperature.
IGF-IR binding studies
DU 145 cells, plated at a density of 1 3 106 cells in 100-mm dishes and
grown in standard culture conditions, were treated with LHRH-A (1026
m final concentration in the cells) for 3 or 6 h. At the end of the treatment,
cells were washed with PBS, scraped, and resuspended in Tris-HCl. The
IGF-IR receptor assay was performed on cell membrane preparations.
[125I]IGF-I (50,000 cpm; 100 ml) was incubated with 100-ml aliquots of cell
membranes and 100 ml unlabeled IGF-I (1027 m). After 1-h incubation
at 22 C, 1 ml ice-cold buffer (10 mm Tris-HCl containing 1 mm dithio-
threitol and 0.15% BSA, pH 7.6) was added, and the tubes were imme-
diately centrifuged at 48,000 3 g for 25 min. Supernatants were dis-
carded, and pellets were counted in a g-counter (Packard Instruments,
Milan, Italy). The maximum binding capacity of each membrane prep-
aration was calculated as previously described (31).
The dissociation constant (Kd) of IGF-IR for each experimental group
was determined by means of displacement curves. [125I]IGF-I was in-
cubated with 100 ml cell membranes in either the absence or presence of
different doses of unlabeled IGF-I (10210-1026 m). Incubations were
performed as described above. The protein content of each membrane
preparation was determined according to the method of Bradford (32).
Western blot analysis of IGFBP-3
DU 145 cells were plated at a density of 5 3 104 cells in 60-mm dishes
and grown under standard conditions. After 2 days, culture media were
changed to serum-free RPMI 1640 medium for 24 h; cells were then
treated with LHRH-A (1028 or 1026 m) or with medium alone for 48 h.
Conditioned media from treated or control cells were concentrated be-
fore electrophoresis through Centriplus-10 microconcentrators (Ami-
con, Beverly, MA) after acidification with 1 m acetic acid to dissociate
IGFs from IGFBPs. Concentrates were lyophilized and submitted to gel
electrophoresis on 12% SDS-polyacrylamide gels. Separated proteins
were transferred to nitrocellulose filters overnight at 4 C with the
IGFBP-3 polyclonal antibody at a final concentration of 1:1000. Filters
were then incubated with goat antirabbit IgG (1:3000). Antibody bound
to IGFBP-3 was detected with the ECL-Western blotting detection sys-
tem after 5- to 10-min exposure to a Hyperfilm-ECL x-ray film (Amer-
sham) at room temperature as described above.
Statistical analysis
The data from proliferation studies were analyzed according to Dun-
nett’s test (33) after one-way ANOVA. The data from displacement
curves for IGF-IR receptors were analyzed by the Ligand computerized
curve-fitting program (34), supplied by the Biochemical Computing
Technology Center (Nashville, TN).
Signals from tyrosine phosphorylation of IGF-IR and IGFBP-3 secre-
tion were quantitated by densitometric analysis and then expressed as
a percentage of the value of IGF-I-induced tyrosine phosphorylation of
IGF-IR and of the control value, respectively.
Results
Cell proliferation studies
DU 145 cells were treated for 7 days with IGF-I (10 ng/ml)
in either the absence or presence of different doses (10210-
1026 m) of LHRH-A. Figure 1 shows that, as expected, IGF-I
exerted a significant stimulatory action on DU 145 cell pro-
liferation. LHRH-A was able to antagonize, in a dose-
dependent way, the mitogenic action of this growth factor;
it significantly counteracted the stimulatory action of IGF-I
when used at either 1028 or 1026 m (Fig. 1). On the basis of
these observations, the dose of 1026 m was selected for the
subsequent experiments.
Tyrosine phosphorylation of IGF-IR
Preliminary experiments were performed to establish the
timing of the activation of the IGF-IR induced by IGF-I. DU
145 cells were treated with the growth factor for different
time intervals up to 10 min. As shown in Fig. 2, the phos-
phorylated IGF-IR b-subunit was detected in a band of ap-
proximately 97 kDa. It appears that IGF-I significantly acti-
vates its receptor at all time intervals considered, starting 1
min after the stimulus. The first time at which maximal
activation occurred (3 min) was used for the subsequent
experiments.
DU 145 cells were treated with LHRH-A (1026 m) for either
30 or 60 min before being exposed to the 3-min stimulus with
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IGF-I. Figure 3A confirms that IGF-I induces the tyrosine
phosphorylation of the IGF-IR b-subunits (lane 2 vs. lane 1).
LHRH-A, when given in the absence of IGF-I, was com-
pletely devoid of any effect (Fig. 3A, lanes 3 and 4). The
pretreatment of DU 145 cells with LHRH-A for 30 or 60 min
substantially counteracted the IGF-dependent phosphoryla-
tion of IGF-IR (Fig. 3A, lanes 5 and 6). Figure 3B provides the
densitometric evaluation of the same results. The inhibitory
effect exerted by the treatment with LHRH-A was very clear
(Fig. 3B, lanes 5 and 6 vs. lane 2).
IGF-IR binding studies
These studies were performed to verify whether LHRH-A
might affect the number and/or the Kd value of IGF-IR in DU
145 cells. Figure 4 shows that LHRH-A, when given for either
3 or 6 h, induced a significant decrease in the concentrations
of IGF-IR at both time intervals considered. The Kd values of
IGF-IR were not affected by the treatment with LHRH-A (Kd
5 1–1.5 nm range in control and treated groups).
Western blot analysis of IGFBP-3
These studies were performed to estimate whether
LHRH-A might change IGFBP-3 secretion from DU 145 cells.
The amount of protein secreted was evaluated by Western
blot analysis in the media of cells treated with LHRH-A (1028
or 1026 m) for 48 h. Figure 5A (lane 1) shows that a protein
band of 45 kDa, corresponding to IGFBP-3, is present in the
culture media of control DU 145 cells. The amount of IGFBP-3
secreted by these cells does not seem to be affected by the
treatment with LHRH-A (Fig. 5A, lanes 2 and 3 vs. lane 1).
Figure 5B provides the densitometric analysis of the same
results.
In agreement with this observation, we also observed that
the messenger RNA levels of IGFBP-3 in DU 145 cells are not
modified by the treatment with LHRH-A (1026 m) for 6–48
h (data not shown). These experiments were performed us-
ing Northern blot analysis with the probe pHBP3–502 (do-
nated by Dr. S. Shimasaki) (35).
FIG. 1. Effect of LHRH-A (10210-1026 M) on the proliferative action
of IGF-I (10 ng/ml) in DU 145 cells. Each experimental group con-
sisted of seven replicates. Each experiment was repeated three times
with identical results. Results are expressed as the mean cell number
per plate 6 SE. M, Controls (C) without drug; f, IGF-I; p, IGF-I plus
LHRH-A. **, P , 0.05 vs. controls; *, P , 0.05 vs. IGF-I.
FIG. 2. Time-dependent stimulation of the IGF-I-induced tyrosine
phosphorylation of the IGF-IR in DU 145 cells. Cells were treated with
IGF-I (75 ng/ml) for 1–10 min. The IGF-IR was immunoprecipitated
and resolved on 7.5% polyacrylamide gels. The amount of phospho-
tyrosine protein on the gel was determined by Western blot using a
specific antibody against phosphotyrosine. One representative of
three experiments is reported.
FIG. 3. Effect of LHRH-A (1026 M) on the IGF-I-induced tyrosine phosphorylation of the IGF-IR in DU 145 cells. LHRH-A was added to the
experimental medium either 30 or 60 min before treatment with IGF-I (75 ng/ml). Lane 1, Controls without drug; lane 2, IGF-I (3 min); lane
3, LHRH-A (30 min); lane 4, LHRH-A (60 min); lane 5, IGF-I plus LHRH-A (30 min); lane 6, IGF-I plus LHRH-A (60 min). A, Representative
Western immunoblot of the tyrosine-phosphorylated IGF-IR. B, Densitometric analysis of tyrosine phosphorylation of IGF-IR. The results are
expressed as a percentage of the value of IGF-I induced tyrosine phosphorylation of IGF-IR and are the mean 6 SE of four separate experiments.
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Discussion
We have previously shown that LHRH agonists exert a
direct antiproliferative action on androgen-independent DU
145 prostate cancer cells (26). The present studies have been
performed to gain additional information on the mechanism
of this antimitogenic action.
IGFs and their binding proteins have been reported to
play a crucial role in the proliferation of androgen-inde-
pendent DU 145 prostate cancer cells (see references in
introduction). The results here reported have shown that
LHRH-A counteracts the proliferative effect of IGF-I, an-
tagonizes the autophopshorylation of IGF-IR, and reduces
the concentration of IGF-IR on DU 145 cell membranes. On
the contrary, LHRH-A does not affect either the secretion
or the expression of IGFBP-3. These observations indicate,
then, that LHRH agonists inhibit the growth of androgen-
independent prostate cancer cells at least partially by in-
terfering with some of the mechanisms mediating the stim-
ulatory action of IGF.
At partial variance with these data, Pinski and co-work-
ers (24) have shown that LHRH agonists do not affect the
concentration of IGF-I receptors in the androgen-indepen-
dent Dunning R-3327-AT-1 rat prostate cancer in vivo. The
different experimental conditions adopted (in vitro vs. in
vivo studies, human vs. rat prostate cancer cells, LHRH
agonist used) might be responsible for this discrepancy.
On the other hand, a significant interaction between
LHRH analogs and the IGF system has been previously
reported for different types of tumors. Yano and co-work-
ers (36) have shown that the LHRH agonist d-Trp6-LHRH
exerts a significant antitumoral activity on the MCF-7 MIII
human breast cancer in nude mice; this effect is accom-
panied by a decrease in the number of IGF-I binding sites.
Moreover, Yano and co-workers (37) have further shown
that the same LHRH agonist is able to inhibit the growth
of OV-1063 human epithelial ovarian cancer xenografts by
reducing the concentration of IGF-I receptors. Finally,
Hershkovitz et al. (38) have reported that a LHRH antag-
onist (SB-75), which has been shown to inhibit the in vitro
proliferation of MCF-7 breast cancer cells, counteracts the
proliferative action of IGF-II on these cells.
The observation that LHRH-A does not affect the secretion
of IGF-BP3 is intriguing. As quoted in the introduction, dif-
ferent IGFBPs are secreted by prostate cancer cells and par-
ticipate in the local regulation of tumor growth by modu-
lating the actions of IGFs. It is then possible that LHRH
agonists might regulate the secretion of IGFBPs different
from IGFBP-3, a possibility that is at present under investi-
gation in our laboratory.
As mentioned in the introduction, we have previously
shown that LHRH agonists exert a direct antiproliferative
action not only on androgen-independent cells, but also on
the androgen-dependent prostate cancer cell line LNCaP
(22, 23). An IGF system is also expressed in these cells,
although their ability to respond to the mitogenic action of
this growth factor seems to be lower than that of steroid-
unresponsive cells (9, 16, 39). Interestingly, preliminary
results obtained in our laboratory indicate that in LNCaP
cells, LHRH-A does not interfere with the activation or the
concentration of IGF receptors; on the contrary, the com-
pound significantly stimulates the secretion of IGFBP-3 in
the culture medium. These results confirm that LHRH
FIG. 4. Effect of LHRH-A (1026 M) on the concentrations of IGF-IR in
DU 145 cells. Each experimental group consisted of seven replicates.
M, Controls without drug; p, LHRH-A. *, P , 0.05 vs. controls.
FIG. 5. Effect of LHRH-A on IGFBP-3 secretion in the culture medium of DU 145 cells treated with LHRH-A. Cells were grown in conditioned
medium for 24 h and then treated with LHRH-A (1028 or 1026 M) for 48 h. Conditioned media from untreated and treated DU 145 cells were
assayed for IGFBP-3 as described in Materials and Methods. Lane 1, Controls without drug; lane 2, LHRH-A (1028 M); lane 3, LHRH-A (1026
M). A, Representative Western immunoblot of IGFBP-3. B, Densitometric analysis of IGFBP-3 levels in culture medium of DU 145 cells. The
results are expressed as a percentage of the control value and are the mean 6 SE of four separate experiments.
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agonists may inhibit prostate cancer cell proliferation by
interfering with the local action of the IGF system; the
molecular mechanisms of this interaction appear to be
different in androgen-dependent and androgen-indepen-
dent cells.
The observation that at the level of prostate cancer, the
mechanism of the antiproliferative action of LHRH-A
might be different according to the androgen dependence
or androgen independence of the cells is in agreement with
previous data from our laboratory (31). We have reported
that LHRH-A interferes with the stimulatory action of the
epidermal growth factor (EGF)/transforming growth fac-
tor-a system, which has been previously shown to par-
ticipate in the local regulation of the growth of this tumor
(40 – 42). In particular, we have shown that in DU 145 cells,
LHRH-A may counteract the mitogenic action of EGF,
inhibit the tyrosine autophosphorylation of the EGF re-
ceptor, and reduce the concentration of EGF binding sites
without modifying the expression of the c-fos protoonco-
gene that follows treatment with the growth factor.
Interestingly, in the androgen-dependent LNCaP cells,
LHRH-A antagonized the proliferative action of EGF by
reducing the concentration of EGF receptors and suppress-
ing the EGF-induced c-fos protooncogene expression with-
out affecting receptor autophosphorylation (31). These ob-
servations further confirm that LHRH agonists exert a
significant antimitogenic action on prostate cancer cells by
interfering with the activity of locally expressed growth
factor systems. However, the molecular mechanisms of
this antiproliferative action differ according to the andro-
gen dependence or androgen independence of the cells
and on the type of growth factor investigated.
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